Evonik

Evonik produces specialty chemicals for a range of industries and is active in more than 100 countries. The Health Care business at Evonik provides a portfolio of functional excipients, technologies and CDMO services for oral and parenteral dosage forms for advanced drug delivery. Evonik also serves as a global CDMO for small molecule APIs, highly potent APIs, and intermediates. For biopharma customers, Evonik supplies high-quality, innovative cell culture solutions and amino acids.

Two key milestones over the past 18 months include the opening of a new facility for clinical and launch quantities of pharmaceutical lipids in Hanau, Germany and officially breaking the ground on a $220 million commercial lipid facility in Lafayette, Indiana – supported with funds from the US government. Evonik also recently started a collaboration with the University of Mainz, Germany, to commercialize a new class of PEG polymers called rPEGs, which could be of particular interest for companies working with lipid nanoparticle carriers. A recent highlight from Evonik’s Drug Substance unit includes the collaboration with Phathom Pharmaceuticals to manufacture the novel acid blocker vonoprazan.